Progressive conduction disease late after adriamycin treatment of lymphoma, despite normalised ejection fraction
Adriamycin (doxorubicin) chemotherapy is known for its acute and late cardiotoxic complications1. In up to 2% of patients they manifest in the form of suppressed ventricular systolic function with its well known consequences, raised filling pressures and mitral regurgitation. Its potential direct ef...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Barcaray International
2014-01-01
|
| Series: | International Cardiovascular Forum Journal |
| Online Access: | http://icfjournal.org/index.php/icfj/article/view/76/68 |